← Leaderboards
Sandra Ann Springer
Yale University
$27,149,168
Attributed
$68,946,875
Total exposure
16
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $21.2M · FY2005–25$25M$18.8M$12.5M$6.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$68,946,875 · 16
By mechanism
U01$37,773,269 · 3
R01$16,018,177 · 4
DP1$4,857,421 · 1
R61$3,687,339 · 3
R33$3,046,675 · 2
UM1$1,418,065 · 1
Top collaborators
- Ank Elisabeth Nijhawan10 shared
- Kevin Knight9 shared
- Frederick Lewis Altice8 shared
- Ya-Chi Ho5 shared
- Yuval Kluger5 shared
- Albert C Shaw5 shared
- Kathleen Theresa Brady4 shared
- Frances Rudnick Levin4 shared
Most similar at Yale University
Same institution · by research overlap
- Frederick Lewis Altice$47,021,698
- Kimberly A Yonkers$18,819,539
- Benjamin G Druss$19,014,914
- Kseniya E Gavrilov$83,035
- Seth Feuerstein$4,840,872
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsCaringCommunitiesPersonsOpioidResponseNaltrexoneBuprenorphineRelapseMethadoneAntiretroviral TherapyResearch PersonnelServicesHiv InfectionsOpioid Use DisorderViralConnecticutSubstance Use DisorderMedicalCriminal JusticeRandomizedEpidemicTrainingAddiction
Grant awards (61)
âGLP-1 Outcomes with people Using Psychoactive Substances (GLOW-UPS): a multi-stage, multi-site trial among persons involved in the criminal-legal system$1,418,065
UM1 · FY2025 · DA
STOP (Shared decision making to Treat Or Prevent) HIV in Justice Populations$1,393,769
R33 · FY2025 · DA · contact PI
Ending HIV: Bringing Integrated Prevention and Treatment Services to People Who Use Drugs Where They Live$1,172,500
DP1 · FY2025 · DA · contact PI
Effects of Medication for Opioid Use Disorder on Microglial Activation and Neurocognition in People Living with HIV$1,162,746
R01 · FY2025 · DA
RESTORE (Recovery and Engagement for STimulant users On Re-entry)$660,104
R61 · FY2025 · DA
Addressing risk through Community Treatment for Infectious disease and Opioid use disorder Now (ACTION) among justice-involved populations$322,746
U01 · FY2025 · DA · contact PI
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults$2,498,125
U01 · FY2024 · DA
Addressing risk through Community Treatment for Infectious disease and Opioid use disorder Now (ACTION) among justice-involved populations$1,926,146
U01 · FY2024 · DA · contact PI
Effects of Medication for Opioid Use Disorder on Microglial Activation and Neurocognition in People Living with HIV$1,213,037
R01 · FY2024 · DA
Ending HIV: Bringing Integrated Prevention and Treatment Services to People Who Use Drugs Where They Live$1,172,500
DP1 · FY2024 · DA · contact PI
STOP (Shared decision making to Treat Or Prevent) HIV in Justice Populations$759,241
R61 · FY2024 · DA · contact PI
Ending HIV: Bringing Integrated Prevention and Treatment Services to People Who Use Drugs Where They Live$167,421
DP1 · FY2024 · DA · contact PI
Addressing risk through Community Treatment for Infectious disease and Opioid use disorder Now (ACTION) among justice-involved populations$2,667,277
U01 · FY2023 · DA · contact PI
Ending HIV: Bringing Integrated Prevention and Treatment Services to People Who Use Drugs Where They Live$1,172,500
DP1 · FY2023 · DA · contact PI
Addressing risk through Community Treatment for Infectious disease and Opioid use disorder Now (ACTION) among justice-involved populations$2,880,406
U01 · FY2022 · DA · contact PI
Coordinated medical treatment of opioid use disorder and infectious disease$1,267,815
U01 · FY2022 · TR · contact PI
Ending HIV: Bringing Integrated Prevention and Treatment Services to People Who Use Drugs Where They Live$1,172,500
DP1 · FY2022 · DA · contact PI
Evaluating the role of opioid medication assisted therapies in HIV-1 Persistence for persons living with HIV and opioid use disorders$814,393
R33 · FY2022 · DA · contact PI
Evaluations of medication assisted treatments for substance use disorders among persons living with and at risk for HIV infection$5,902
K02 · FY2022 · DA · contact PI
Addressing risk through Community Treatment for Infectious disease and Opioid use disorder Now (ACTION) among justice-involved populations$2,665,428
U01 · FY2021 · DA · contact PI
Coordinated medical treatment of opioid use disorder and infectious disease$1,347,367
U01 · FY2021 · TR · contact PI
Evaluating the role of opioid medication assisted therapies in HIV-1 Persistence for persons living with HIV and opioid use disorders$838,513
R33 · FY2021 · DA · contact PI
Evaluations of medication assisted treatments for substance use disorders among persons living with and at risk for HIV infection$123,838
K02 · FY2021 · DA · contact PI
Addressing risk through Community Treatment for Infectious disease and Opioid use disorder Now (ACTION) among justice-involved populations$88,275
U01 · FY2021 · DA · contact PI
Addressing risk through Community Treatment for Infectious disease and Opioid use disorder Now (ACTION) among justice-involved populations$1,544,013
U01 · FY2020 · DA · contact PI
Coordinated medical treatment of opioid use disorder and infectious disease$1,353,900
U01 · FY2020 · TR · contact PI
The Impact of HIV Infection on Immunologic, Transcriptomic, and Metabolomic Signatures of Medication-Assisted Therapy for Opioid Addiction$1,148,831
R01 · FY2020 · DA · contact PI
Evaluating the role of opioid medication assisted therapies in HIV-1 Persistence for persons living with HIV and opioid use disorders$767,108
R61 · FY2020 · DA · contact PI
Evaluations of medication assisted treatments for substance use disorders among persons living with and at risk for HIV infection$123,838
K02 · FY2020 · DA · contact PI
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults$17,761,674
U01 · FY2019 · DA
Coordinated medical treatment of opioid use disorder and infectious disease$1,450,097
U01 · FY2019 · TR · contact PI
The Impact of HIV Infection on Immunologic, Transcriptomic, and Metabolomic Signatures of Medication-Assisted Therapy for Opioid Addiction$1,148,831
R01 · FY2019 · DA · contact PI
Evaluating the role of opioid medication assisted therapies in HIV-1 Persistence for persons living with HIV and opioid use disorders$739,893
R61 · FY2019 · DA · contact PI
Evaluations of medication assisted treatments for substance use disorders among persons living with and at risk for HIV infection$123,838
K02 · FY2019 · DA · contact PI
The Impact of HIV Infection on Immunologic, Transcriptomic, and Metabolomic Signatures of Medication-Assisted Therapy for Opioid Addiction$1,148,831
R01 · FY2018 · DA · contact PI
Evaluating the role of opioid medication assisted therapies in HIV-1 Persistence for persons living with HIV and opioid use disorders$760,993
R61 · FY2018 · DA · contact PI
Evaluations of medication assisted treatments for substance use disorders among persons living with and at risk for HIV infection$123,838
K02 · FY2018 · DA · contact PI
The Impact of HIV Infection on Immunologic, Transcriptomic, and Metabolomic Signatures of Medication-Assisted Therapy for Opioid Addiction$1,148,831
R01 · FY2017 · DA · contact PI
The Impact of HIV Infection on Immunologic, Transcriptomic, and Metabolomic Signatures of Medication-Assisted Therapy for Opioid Addiction$1,161,477
R01 · FY2016 · DA · contact PI
Medication Assisted Therapy as a Conduit to Care for HIV+ CJS Populations Transit$154,235
K02 · FY2015 · DA · contact PI
Naltrexone for Opioid Dependent Released HIV+ Criminal Justice Populations$149,850
R01 · FY2015 · DA · contact PI
Naltrexone for Opioid Dependent Released HIV+ Criminal Justice Populations$726,374
R01 · FY2014 · DA · contact PI
Medication Assisted Therapy as a Conduit to Care for HIV+ CJS Populations Transit$154,235
K02 · FY2014 · DA · contact PI
Naltrexone for Opioid Dependent Released HIV+ Criminal Justice Populations$769,553
R01 · FY2013 · DA · contact PI
Alcohol Pharmacotherapies Among Released Prisoners$704,307
R01 · FY2013 · AA · contact PI
Medication Assisted Therapy as a Conduit to Care for HIV+ CJS Populations Transit$154,235
K02 · FY2013 · DA · contact PI
Naltrexone for Opioid Dependent Released HIV+ Criminal Justice Populations$834,318
R01 · FY2012 · DA · contact PI
Alcohol Pharmacotherapies Among Released Prisoners$774,586
R01 · FY2012 · AA · contact PI
Medication Assisted Therapy as a Conduit to Care for HIV+ CJS Populations Transit$154,235
K02 · FY2012 · DA · contact PI
Naltrexone for Opioid Dependent Released HIV+ Criminal Justice Populations$822,487
R01 · FY2011 · DA · contact PI
Alcohol Pharmacotherapies Among Released Prisoners$760,400
R01 · FY2011 · AA · contact PI
Medication Assisted Therapy as a Conduit to Care for HIV+ CJS Populations Transit$154,235
K02 · FY2011 · DA · contact PI
Naltrexone for Opioid Dependent Released HIV+ Criminal Justice Populations$780,884
R01 · FY2010 · DA · contact PI
Alcohol Pharmacotherapies Among Released Prisoners$761,595
R01 · FY2010 · AA · contact PI
Alcohol Pharmacotherapies Among Released Prisoners$41,210
R01 · FY2010 · AA · contact PI
Alcohol Pharmacotherapies Among Released Prisoners$760,029
R01 · FY2009 · AA · contact PI
Opiate Dependence, HIV and Adherence Interventions$180,366
K23 · FY2009 · DA · contact PI
Opiate Dependence, HIV and Adherence Interventions$180,366
K23 · FY2008 · DA · contact PI
Opiate Dependence, HIV and Adherence Interventions$178,793
K23 · FY2007 · DA · contact PI
Opiate Dependence, HIV and Adherence Interventions$175,158
K23 · FY2006 · DA · contact PI
Opiate Dependence, HIV and Adherence Interventions$158,817
K23 · FY2005 · DA